1190391-63-9

Basic information

• Product Name: (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid
• Synonyms: (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid
• CAS NO: 1190391-63-9
• Molecular Weight: 332.515
• Mol File: 1190391-63-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid(1190391-63-9)
• EPA Substance Registry System: (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid(1190391-63-9)

Safety Data

• Hazardous Substances Data: 1190391-63-9(Hazardous Substances Data)

Upstream product

• 1558057-38-7 (S)-4-benzyl-3-((R)-2-((S)-hydroxy(phenyl)methyl)hex-5-ynoyl)oxazolidin-2-one 
• 1190614-95-9 (4S)-3-hex-5-ynoyl-4-benzyl-1,3-oxazolidin-2-one 
• 100-52-7 benzaldehyde 
• 1190391-61-7 (4S)-3-{(2R)-2-[(S)-hydroxy(phenyl)methyl]hex-5-ynoyl}-4-phenyl-1,3-oxazolidin-2-one 
• 1190391-59-3 (S)-3-(hex-5-ynoyl)-4-phenyloxazolidin-2-one 
• 53293-00-8 hex-5-ynoic acid 
• 1190391-62-8 (2R)-2-[(S)-hydroxy(phenyl)methyl]hex-5-ynoic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1190391-64-0 4-methoxybenzyl {(1R)-1-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pent-4-yn-1-yl}carbamate 
• 1190391-57-1 tert-butyl (2S,5R)-2-(4-aminobenzyl)-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pyrrolidine-1-carboxylate 
• 1190391-65-1 4-methoxybenzyl [(1R)-1-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-5-(4-nitrophenyl)pent-4-yn-1-yl]carbamate 
• 1190391-66-2 4-methoxybenzyl ((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-6-(4-nitrophenyl)-5-oxo-1-phenylhexan-2-yl)carbamate 
• 1190391-68-4 (2R,5R)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-5-(4-nitrobenzyl)pyrrolidine 
• 1346171-55-8 tert-butyl (2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-5-({2-[(1S)-1-(2-oxopyrimidin-1(2H)-yl)ethyl]-1H-benzimidazol-6-yl}methyl)pyrrolidine-1-carboxylate 
• 1346171-03-6 1-{(1S)-1-[6-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)-1H-benzimidazol-2-yl]ethyl}pyrimidin-2(1H)-one 
• 1190391-67-3 (2R,5S)-2-((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-5-(4-nitrobenzyl)pyrrolidine 
• 1190391-69-5 tert-butyl (2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-5-(4-nitrobenzyl)pyrrolidine-1-carboxylate 
• 1346171-52-5 tert-butyl (2S,5R)-2-(4-amino-3-nitrobenzyl)-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pyrrolidine-1-carboxylate 
• 1346171-53-6 tert-butyl (2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-5-(3,4-diaminobenzyl)pyrrolidine-1-carboxylate 
• 1346171-54-7 tert-butyl (2S,5R)-2-(3-amino-4-{[(2S)-2-(2-oxopyrimidin-1(2H)-yl)propanoyl]amino}benzyl)-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pyrrolidine-1-carboxylate 
• 1190390-46-5 N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-{4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}benzenesulfonamide 
• 1190393-26-0 tert-butyl(2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl-5-(4-{[(4-{4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}phenyl)sulfonyl]amino}benzyl)pyrrolidine]-1-carboxylate 

Relevant articles and documents

Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder

The synthesis of a novel class of piperazine benzamide (reverse amides) targeting the human β3-adrenergic receptor for the treatment of overactive bladder (OAB) is described. The SAR studies directed towards maintaining well established β3 potency and selectivities while improving the overall pharmacokinetic profile in the reverse amide class will be evaluated. The results and consequences associated with functional activity at the norepinephrine transporter (NET) will also be discussed.

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.